Pancreatic cancer clinical trials — what taking part actually involves

A clinical trial is a research study that runs to a written protocol. The protocol sets out who can join, exactly what is given, what is measured and when, and what happens if things go wrong. Nothing in it is decided appointment by appointment. That is the most useful thing to understand about pancreatic cancer clinical trials: taking part means following a written plan that was reviewed and approved before the first patient joined it.

The word most people react to is “experimental.” In a registered study it means the treatment is being tested against a defined question, under supervision, with your consent in writing and your right to stop at any time. It does not mean a doctor is trying something out on you. A study run in India is expected to be entered on the Clinical Trials Registry – India before recruitment begins, and to be approved by a registered ethics committee. Both of those are checkable, and you are entitled to ask for both.

A trial is also not a last resort. Studies exist at almost every point in the pathway — before surgery, after surgery, alongside first systemic treatment, at a later line, and in symptom control and supportive care. Some are open only to people who have had no treatment at all. Reading how chemotherapy is used at each stage of pancreatic cancer makes it far easier to see where a study would sit in your own plan, because most studies are built around standard treatment rather than instead of it.

What a trial cannot be is a promise. A study exists because the answer is genuinely not known yet. Some tested treatments turn out to be better than what we use now, some turn out to be the same, and some turn out to be worse or harder to tolerate. Anyone who tells you the outcome in advance is not describing research. For the wider picture of diagnosis, treatment and support, the complete pancreatic cancer guide is the place to start.

• What question is this study asking, and what phase is it? The phase tells you whether the study is testing safety, activity or superiority — and how much is already known about what you would be given.
• What are the arms, and how is mine decided? Ask whether it is single-arm or randomised, what the comparison arm receives, and whether anyone is blinded to the allocation.
• What does the schedule commit me to? Extra visits, extra scans, extra blood tests, appointment windows that cannot drift, and travel to the study centre are the parts most often underestimated.
• What does the study pay for, and what am I still billed for? Study treatment and study-specific tests are usually covered by the study; routine care around them may not be. Get the split in writing before you sign.
• What happens if I decline, or leave part-way through? The answer should be that standard treatment continues without prejudice — see what standard pancreatic cancer treatment in Hyderabad involves.
• Is it registered, and which ethics committee approved it? If an “experimental treatment” has no registry entry, no ethics approval, an upfront price and a promise of cure, it is not research. Take the paperwork for a free written second opinion before you commit to anything.

1. 1

   Read the reports properly first

   The pathology report and the staging scan decide which studies could ever apply to you. Adenocarcinoma and neuroendocrine tumours recruit to entirely different studies, so the tumour type is settled before anything else is discussed.

   Free 45-minute consultation
2. 2

   Establish what standard treatment still offers

   A study is only worth weighing against the alternative. We set out what proven treatment would give you now — surgery-directed, systemic or radiation-based — so the comparison is real rather than theoretical.

   In-house at CION
3. 3

   Check what would make you eligible, or not

   Performance status, blood counts, liver and kidney function, previous lines of treatment, whether a blocked bile duct has been drained, and biomarker findings all matter. Genetic counselling and testing sit here, because an inherited finding can open or close a door.

   In-house at CION
4. 4

   Read the consent document together

   We go through the schedule, the extra tests, the travel, the withdrawal clause and the billing split, and write down the questions worth putting to the study team before you sign anything.

   Free 45-minute consultation
5. 5

   Coordinate with the centre running the study

   Screening, enrolment and the study treatment itself are handled by the study team at their own centre, under their protocol and their billing arrangements. We send the reports across and stay in the conversation.

   Coordinated with the study centre
6. 6

   Keep your plan going, either way

   If you decide against a study, or come off one, standard treatment carries on with us across 35+ centres — chemotherapy, radiation, nutrition and enzyme support, pain relief and follow-up, without you starting again from scratch.

   In-house at CION

Your first consultation is free and lasts 45 minutes. It is a proper review of your reports and your options, including any study you have been offered, rather than a booking appointment. We will not promise you a place on a study — that decision belongs to the study team and its ethics committee, and anyone who guarantees it in advance is telling you something they cannot know.

Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology — chemotherapy before surgery, after surgery and for advanced disease; PARP-inhibitor-class maintenance where an inherited BRCA change is found; immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient; and systemic treatment for neuroendocrine tumours, including somatostatin-analogue-class therapy. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods; genetic counselling and testing; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.

Coordinated with specialist partner centres, and may be billed there: all pancreatic surgery; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. Screening, enrolment and treatment under a study protocol sit with the centre running that study, on its own terms. We arrange the referral, send the reports, and tell you in advance where each step happens and who invoices you. We do not describe any of it as our own service, because it is not.

Medical disclaimer: This page explains what taking part in a pancreatic cancer clinical trial generally involves and is reviewed by a CION medical oncologist, with reference to NCCN guidance on the place of clinical trials in cancer care. It is general information, not advice on any particular study, and no study treatment is offered or promised here; whether a study is suitable for you depends on your own pathology, imaging, fitness and previous treatment, and enrolment is decided by the study team and its ethics committee. Report review and eligibility assessment, chemotherapy, radiation, chemoradiation and SBRT, diagnostic ordering and reporting, CA 19-9 and bloods, genetic counselling and testing, nutrition and pancreatic enzyme (PERT) support, pain, psycho-oncology and supportive care and survivorship follow-up are delivered by CION. All pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET and PRRT are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there, and trial screening, enrolment and protocol treatment sit with the centre running the study.